Question 1

What is the life expectancy of someone with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia, does not typically affect life expectancy, which is generally considered to be normal. Because this condition is a movement disorder rather than a neurodegenerative disease, patients can expect a typical lifespan, provided they receive appropriate clinical management.

What is the long-term prognosis for Paroxysmal Kinesigenic Dyskinesia?
The long-term prognosis for Paroxysmal Kinesigenic Choreathetosis is generally very positive. While the sudden, involuntary movements associated with Paroxysmal Kinesigenic Dyskinesia can be distressing, the condition does not cause permanent brain damage or progressive neurological decline. Many individuals find that the frequency of these episodes decreases as they enter adulthood, and some may even experience a spontaneous remission of symptoms over time.

How do treatments influence quality of life in Paroxysmal Kinesigenic Choreathetosis?
While life expectancy remains unaffected, the primary clinical focus is on the patient's quality of life. Paroxysmal Kinesigenic Dyskinesia is highly responsive to low-dose anticonvulsant medications, such as carbamazepine or oxcarbazepine. When these medications are managed correctly by a neurologist, patients often achieve near-total control of their symptoms. Effective symptom management is critical to preventing social anxiety and the physical risks associated with unexpected movement episodes.

What factors affect the management of Paroxysmal Kinesigenic Choreathetosis?
Several factors contribute to successful long-term outcomes for those living with Paroxysmal Kinesigenic Choreathetosis:

Early Diagnosis: Identifying Paroxysmal Kinesigenic Dyskinesia early prevents unnecessary diagnostic testing and allows for the prompt initiation of effective pharmacotherapy.
    Treatment Adherence: Consistent use of prescribed medications is the most significant factor in reducing the frequency of choreathetic attacks.
    Trigger Identification: Recognizing specific movement-based triggers helps patients navigate daily activities more safely.
    Regular Medical Follow-up: Ongoing monitoring with a specialist ensures medication dosages are adjusted as needed throughout the patient's life.

Next steps

Consult a neurologist specializing in movement disorders to discuss personalized medication strategies.
    Connect with the 7 members of the DiseaseMaps.org community living with Paroxysmal Kinesigenic Choreathetosis to share experiences and coping mechanisms.
    Keep a detailed diary of your triggers and episodes to assist your physician in fine-tuning your treatment plan.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:1820).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, PKSD (#128200).

Question 2

Celebrities with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia

Accepted Answer

Currently, there are no widely known public figures or celebrities who have publicly disclosed a diagnosis of Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD). Because Paroxysmal Kinesigenic Choreathetosis is a rare neurological disorder, awareness is primarily driven by medical researchers, patient advocacy organizations, and the small, dedicated community of patients sharing their lived experiences.

Why is public awareness of Paroxysmal Kinesigenic Choreathetosis limited?
Paroxysmal Kinesigenic Choreathetosis is an extremely rare condition, often misdiagnosed as epilepsy or psychogenic movement disorders due to its sudden, brief nature. Because it is not a "household name," media attention remains low. However, the 7 members of the DiseaseMaps.org community living with Paroxysmal Kinesigenic Choreathetosis play a crucial role in documenting the reality of the condition. By sharing their experiences, these patients help bridge the gap between clinical data and the daily challenges of living with unpredictable, movement-triggered involuntary muscle contractions.

How does patient advocacy impact Paroxysmal Kinesigenic Choreathetosis research?
In the absence of celebrity disclosure, the burden of advocacy falls on specialized neurological foundations and the rare disease community. Advocacy efforts have been vital in identifying the genetic basis of Paroxysmal Kinesigenic Choreathetosis, specifically mutations in the PRRT2 gene. Increased awareness helps ensure that:

Patients receive faster, more accurate diagnoses from movement disorder specialists.
    Clinical researchers receive more interest in studying the efficacy of anticonvulsants, such as carbamazepine, which are often highly effective for this condition.
    Funding for genetic screening increases, helping families understand the autosomal dominant inheritance pattern of Paroxysmal Kinesigenic Choreathetosis.

What are the primary goals for the Paroxysmal Kinesigenic Choreathetosis community?
The primary focus for those affected by Paroxysmal Kinesigenic Choreathetosis is to differentiate the condition from other forms of dyskinesia. Key objectives include:

Educating primary care physicians to recognize the "kinesigenic" trigger—movements that induce attacks lasting less than one minute.
    Promoting the use of genetic testing to confirm PRRT2-related Paroxysmal Kinesigenic Choreathetosis.
    Reducing the social stigma associated with sudden, involuntary movements in public settings.

Next steps

Consult a neurologist specializing in movement disorders to discuss potential medication management.
    Connect with the 7 members at DiseaseMaps.org to share your journey and learn from others.
    Review the latest clinical literature on PRRT2-related disorders via NIH GARD to stay informed on treatment options.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA: 247605)
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, 1; FTD1

Question 3

Is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia hereditary?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is a genetic condition typically inherited in an autosomal dominant pattern. While most cases are hereditary, approximately 10-20% of cases may arise from de novo (spontaneous) mutations, meaning the condition occurs in an individual without a prior family history.

Is Paroxysmal Kinesigenic Choreathetosis hereditary?
Yes, Paroxysmal Kinesigenic Choreathetosis is primarily a hereditary condition. It is most commonly associated with mutations in the PRRT2 gene, which is located on chromosome 16. Because it follows an autosomal dominant inheritance pattern, an individual with a pathogenic PRRT2 mutation has a 50% chance of passing the condition to each of their children.

How do genetic factors influence Paroxysmal Kinesigenic Dyskinesia?
The PRRT2 gene provides instructions for making a protein involved in neurotransmitter release. In families with Paroxysmal Kinesigenic Choreathetosis, a single altered copy of this gene in each cell is sufficient to cause the disorder. It is important to note that the condition exhibits "incomplete penetrance," meaning some individuals who carry the mutation may never experience symptoms, or may present with related conditions like infantile convulsions.

Is genetic testing available for Paroxysmal Kinesigenic Choreathetosis?
Clinical genetic testing is available and is highly recommended to confirm a diagnosis of Paroxysmal Kinesigenic Dyskinesia. Testing typically involves sequencing the PRRT2 gene. Key considerations for families include:

Diagnostic confirmation: Provides clarity for patients experiencing episodic movement symptoms.
    Family screening: Allows relatives to understand their own risk of developing Paroxysmal Kinesigenic Choreathetosis.
    Reproductive planning: Genetic counseling can help families understand the 50% recurrence risk and discuss options like preimplantation genetic testing (PGT).
    De novo occurrences: If no family history is present, testing can determine if the mutation occurred spontaneously in the affected individual.

Next steps

Consult a clinical geneticist to discuss whether PRRT2 testing is appropriate for your family.
    Connect with the 7 members of the Paroxysmal Kinesigenic Choreathetosis community at DiseaseMaps.org to share experiences and coping strategies.
    Maintain a detailed symptom log to help your neurologist distinguish Paroxysmal Kinesigenic Dyskinesia from other paroxysmal movement disorders.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult a qualified healthcare professional for diagnosis and management.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:2546).
    OMIM (Online Mendelian Inheritance in Man): Paroxysmal Kinesigenic Dyskinesia 1 (PKD1; #128200).
    PubMed: Review of PRRT2-associated paroxysmal neurological disorders.

Question 4

Is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia contagious?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is not a contagious condition and cannot be transmitted to others through touch, proximity, or social interaction. It is a neurological disorder primarily driven by genetic mutations, meaning there is zero risk of "catching" this disease from a friend, family member, or colleague.

What causes Paroxysmal Kinesigenic Choreathetosis?
Paroxysmal Kinesigenic Choreathetosis is primarily a genetic movement disorder. In a significant number of cases, it is caused by mutations in the PRRT2 gene, which plays a crucial role in neurotransmitter release. Because it is rooted in your DNA, it is biologically impossible for it to spread like a virus or infection. The condition manifests as brief, recurrent episodes of involuntary movements triggered by sudden voluntary motion.

Why is there confusion regarding contagion?
Because Paroxysmal Kinesigenic Dyskinesia involves sudden, involuntary physical movements, bystanders unfamiliar with the condition may mistakenly fear it is an infectious outbreak or a behavioral contagion. This stigma is entirely unfounded. Paroxysmal Kinesigenic Choreathetosis is a physiological reaction to specific neurological stimuli, and the 7 members of our DiseaseMaps community living with this condition face no risk to their peers or loved ones.

Are there environmental triggers for Paroxysmal Kinesigenic Dyskinesia?
While the condition is not contagious, it is highly sensitive to specific environmental and physical triggers. These include:

Sudden voluntary movement: Standing up quickly or starting to run.
    Startle response: Sudden noises or unexpected physical contact.
    Emotional stress: Heightened anxiety or excitement can sometimes lower the threshold for an attack.
    Fatigue: Lack of sleep or physical exhaustion may increase the frequency of episodes.

Next steps

Consult a neurologist specializing in movement disorders to discuss genetic testing for the PRRT2 gene.
    Join our community at DiseaseMaps.org to connect with others who understand the reality of living with Paroxysmal Kinesigenic Choreathetosis.
    Educate family and friends about the non-contagious nature of Paroxysmal Kinesigenic Dyskinesia to reduce unnecessary social anxiety.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:1669).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, familial kinesigenic, 1; FKS1 (#128200).

Question 5

ICD10 code of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia and ICD9 code

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), does not have a unique, dedicated ICD-10 or ICD-9 code. Clinicians typically use the ICD-10 code G25.0 (Drug-induced subacute dyskinesia) or G25.89 (Other specified extrapyramidal and movement disorders), while ICD-9-CM utilized 333.89 (Other specified extrapyramidal disease and abnormal movement disorders) for coding this condition.

Why is there no specific ICD code for Paroxysmal Kinesigenic Choreathetosis?
Because Paroxysmal Kinesigenic Choreathetosis is a rare movement disorder, it is often grouped under broader categories of "extrapyramidal and movement disorders" in international billing systems. This lack of a specific code can sometimes make insurance billing or tracking of Paroxysmal Kinesigenic Dyskinesia patients challenging, as practitioners must rely on descriptive codes that encompass various involuntary movement syndromes.

What are the primary features of Paroxysmal Kinesigenic Choreathetosis?
Paroxysmal Kinesigenic Dyskinesia is characterized by brief, sudden attacks of involuntary movements triggered by a sudden change in activity or movement. Symptoms typically include:

Dystonic posturing or choreoathetoid movements lasting less than one minute.
    Onset typically occurring in childhood or adolescence (usually between ages 5 and 15).
    High frequency of attacks, sometimes occurring dozens of times per day.
    Clear triggers such as standing up quickly, starting to run, or sudden emotional startle.
    Excellent response to low-dose anticonvulsants like carbamazepine or oxcarbazepine.

Is Paroxysmal Kinesigenic Dyskinesia hereditary?
In many cases, Paroxysmal Kinesigenic Choreathetosis is an inherited condition. Approximately 50% of familial cases are linked to mutations in the PRRT2 gene, which follows an autosomal dominant inheritance pattern. Understanding the genetic basis of Paroxysmal Kinesigenic Dyskinesia is vital for accurate diagnosis and family planning.

Next steps

Consult a movement disorder neurologist to confirm a clinical diagnosis of Paroxysmal Kinesigenic Choreathetosis.
    Consider genetic testing for the PRRT2 gene mutation to confirm the diagnosis.
    Join the DiseaseMaps.org community to connect with the 7 other members currently living with this condition.
    Maintain a symptom diary to help your physician optimize your anticonvulsant dosage.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA: 247608).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, 1 (Entry #128200).
    International Parkinson and Movement Disorder Society (MDS) clinical guidelines.

Question 6

Is there any natural treatment for Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Currently, there are no scientifically validated natural or herbal treatments capable of curing or managing the underlying pathophysiology of Paroxysmal Kinesigenic Choreathetosis (PKC). While conventional anticonvulsant medications remain the gold standard for clinical management, patients often explore lifestyle adjustments to reduce the frequency of their episodic, movement-induced attacks.

Are there natural remedies for Paroxysmal Kinesigenic Choreathetosis?
There is no robust clinical evidence supporting the use of herbal supplements or alternative therapies for Paroxysmal Kinesigenic Choreathetosis. Because this condition is often linked to mutations in the PRRT2 gene, it is considered a neurological channelopathy that generally requires pharmacological intervention, such as low-dose carbamazepine or oxcarbazepine, to stabilize neuronal membranes. Always consult your neurologist before adding any supplement, as some substances may interact with anti-seizure medications.

How do lifestyle modifications impact symptom frequency?
For individuals living with Paroxysmal Kinesigenic Choreathetosis, identifying and avoiding specific movement triggers is the most effective "natural" strategy. Many patients report that sudden voluntary movements—such as standing up quickly or starting to run—precipitate their dystonic or choreoathetoid attacks. Practical management steps include:

Trigger Identification: Keeping a detailed diary to track movements or emotional states that precede an attack.
    Gradual Movement: Transitioning between positions slowly to avoid the sudden, jerky movements that often trigger symptoms of Paroxysmal Kinesigenic Choreathetosis.
    Stress Reduction: While stress is not the primary cause, anxiety can lower the threshold for episodes in some patients.
    Sleep Hygiene: Maintaining a consistent sleep schedule, as fatigue is frequently reported as a secondary trigger by our community members.

Can mind-body practices help manage the condition?
While practices like yoga, meditation, and acupuncture cannot stop the physiological mechanism of Paroxysmal Kinesigenic Choreathetosis, they may assist in managing the psychological burden of living with a chronic, unpredictable movement disorder. There is no evidence that these practices reduce the frequency of attacks in Paroxysmal Kinesigenic Choreathetosis, but they can improve overall quality of life and help patients cope with the frustration of episodic symptoms.

Next steps

Consult a movement disorder specialist to confirm your diagnosis and optimize your medication dosage.
    Join our DiseaseMaps community to connect with other patients who understand the daily challenges of Paroxysmal Kinesigenic Choreathetosis.
    Discuss any new supplement or lifestyle change with your neurologist to ensure safety.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice; always consult your physician before changing your treatment plan.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:2472).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, 1 (Entry #128200).
    PubMed: Review of PRRT2-associated paroxysmal neurological disorders.

Question 7

Living with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia. How to live with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Living with Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia, involves managing sudden, brief movement attacks often triggered by voluntary motion. While these episodes can be distressing, most individuals lead full lives by utilizing targeted anticonvulsant therapies and developing personalized psychological coping strategies to navigate the unpredictability of the condition.

What is the emotional impact of living with Paroxysmal Kinesigenic Choreathetosis?
The unpredictability of Paroxysmal Kinesigenic Choreathetosis can create significant anxiety, as patients often worry about having an attack in public or professional settings. This "anticipatory anxiety" is common, but you are not alone; our DiseaseMaps.org community currently connects 7 individuals who share these exact experiences. Acknowledging that your feelings of frustration or social apprehension are valid responses to a chronic, rare condition is the first step toward building psychological resilience.

How can I manage the challenges of Paroxysmal Kinesigenic Dyskinesia?
Practical management of Paroxysmal Kinesigenic Dyskinesia often requires a blend of medical adherence and lifestyle adjustments. Patients frequently report that the following strategies help reduce the stress associated with the condition:

Keep a symptom diary: Tracking triggers helps you and your neurologist identify patterns, which can restore a sense of agency.
    Educate your circle: Sharing information about Paroxysmal Kinesigenic Choreathetosis with friends and colleagues can reduce the fear of "being misunderstood" during an episode.
    Practice grounding techniques: Mindfulness and deep breathing can help regulate your nervous system during or after an attack.
    Focus on meaningful pursuits: Prioritize hobbies that are less likely to trigger dyskinesia, allowing you to maintain a sense of purpose and joy.

When should I seek professional mental health support?
If the stress of managing Paroxysmal Kinesigenic Choreathetosis begins to interfere with your ability to sleep, work, or maintain relationships, it is time to consult a therapist. A clinical psychologist specializing in chronic illness can provide cognitive behavioral therapy (CBT) tailored to the unique stressors of living with a rare, movement-related condition.

Next steps

Connect with the 7 members at DiseaseMaps.org to share your journey and find peer support.
    Consult a movement disorder specialist to ensure your treatment plan for Paroxysmal Kinesigenic Dyskinesia is optimized.
    Join a patient advocacy group to stay informed about the latest clinical research.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:98863).
    Online Mendelian Inheritance in Man (OMIM): Paroxysmal Kinesigenic Dyskinesia (Entry #128200).

Question 8

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia diet. Is there a diet which improves the quality of life of people with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

There is currently no evidence-based, disease-specific diet that treats Paroxysmal Kinesigenic Choreathetosis (PKC), as the condition is primarily a neurological movement disorder rather than a metabolic one. While no specific dietary protocol has been proven to stop attacks, maintaining a stable blood glucose level through regular, balanced nutrition can help avoid physiological stressors that might lower the threshold for Paroxysmal Kinesigenic Choreathetosis episodes.

Is there a specific diet for Paroxysmal Kinesigenic Choreathetosis?
No, there is no medical consensus or clinical literature supporting a specific "PKC diet." Because Paroxysmal Kinesigenic Choreathetosis is often caused by mutations in the PRRT2 gene, dietary changes cannot correct the underlying ion channel dysfunction. However, our community of 7 members at DiseaseMaps.org often reports that general wellness and metabolic stability are key to managing overall quality of life.

Are there foods or substances to avoid with Paroxysmal Kinesigenic Choreathetosis?
While food does not trigger Paroxysmal Kinesigenic Choreathetosis directly, certain substances may exacerbate neurological excitability. We recommend monitoring the following:

Excessive Caffeine: High doses of stimulants can increase anxiety and physiological arousal, which may lower the seizure threshold in some patients.
    Alcohol: Alcohol can interfere with the efficacy of anticonvulsants (such as carbamazepine) often prescribed for Paroxysmal Kinesigenic Choreathetosis and may disrupt sleep, a known trigger for movement disorders.
    High-Sugar/High-Glycemic Foods: Rapid spikes and crashes in blood sugar can cause physical stress, which some patients report as a precursor to symptoms.

How do medications for Paroxysmal Kinesigenic Choreathetosis interact with nutrition?
Most patients with Paroxysmal Kinesigenic Choreathetosis are managed with low-dose anticonvulsants like carbamazepine or oxcarbazepine. It is vital to note that grapefruit and grapefruit juice can interact with these medications by altering their metabolism in the liver, potentially leading to toxic levels or decreased effectiveness. Always consult your neurologist before adding supplements or making major dietary shifts.

Next steps

Consult a neurologist to confirm your medication dosage is optimized.
    Keep a food and symptom diary for one month to identify if specific stressors correlate with your attacks.
    Join our community at DiseaseMaps.org to connect with others sharing experiences with Paroxysmal Kinesigenic Choreathetosis.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always consult your physician before making any changes to your diet or medical regimen.

References

NIH Genetic and Rare Diseases Information Center (GARD) on Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:2472).
    OMIM (Online Mendelian Inheritance in Man): Entry #128200 (PRRT2-related disorders).
    Journal of Neurology, Neurosurgery & Psychiatry: Clinical reviews on PRRT2-associated movement disorders.

Question 9

What is the history of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), was first formally characterized in the mid-20th century, evolving from a misunderstood movement disorder into a recognized genetic channelopathy. Historically viewed as a psychiatric condition, modern research has identified its roots in the PRRT2 gene, leading to precise diagnostic and treatment standards.

When was Paroxysmal Kinesigenic Choreathetosis first described?
While reports of transient movement disorders appeared in the early 1900s, Paroxysmal Kinesigenic Choreathetosis was distinctly defined in 1967 by Dr. George R. H. Kato, who coined the term "paroxysmal kinesigenic choreoathetosis." Before this, patients were frequently misdiagnosed with epilepsy or conversion disorders due to the sudden, involuntary nature of the movements, which are triggered by unexpected physical motion.

How has the understanding of Paroxysmal Kinesigenic Dyskinesia evolved?
For decades, clinicians struggled to classify whether Paroxysmal Kinesigenic Dyskinesia was a form of epilepsy. It was only through the advancement of neurogenetics in 2011 that researchers discovered mutations in the PRRT2 (Proline-rich transmembrane protein 2) gene. This breakthrough confirmed that the disease is a channelopathy—a disorder of ion channels in the brain—rather than a psychological or seizure-based condition.

What are the major milestones in managing this condition?
The history of treatment for Paroxysmal Kinesigenic Choreathetosis has shifted from trial-and-error to targeted management. Key milestones include:

1960s-70s: Initial discovery that anticonvulsants, particularly phenytoin, could suppress attacks.
1980s: Recognition of carbamazepine as a highly effective, low-dose maintenance therapy.
2011: Identification of the PRRT2 gene, allowing for definitive genetic testing.
Modern Era: Shift toward personalized medicine, minimizing the trial of unnecessary psychiatric medications.

How has patient awareness changed?
Historical misconceptions often led to social stigma for those living with Paroxysmal Kinesigenic Dyskinesia. Today, platforms like DiseaseMaps.org empower the 7 community members currently registered to share experiences, replacing isolation with shared clinical knowledge. Increased awareness ensures that patients are now directed to neurologists specializing in movement disorders rather than psychiatric care.

Next steps

Consult a movement disorder specialist or neurologist for a formal evaluation.
Discuss PRRT2 genetic testing with a clinical geneticist to confirm a diagnosis.
Join the DiseaseMaps.org community to connect with others managing Paroxysmal Kinesigenic Choreathetosis.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH GARD (Genetic and Rare Diseases Information Center) - Paroxysmal Kinesigenic Dyskinesia.
Orphanet (ORPHA:168536) - Paroxysmal kinesigenic choreoathetosis.
OMIM (Online Mendelian Inheritance in Man) - #128200 (PKD1).
PubMed: "The clinical and genetic spectrum of PRRT2-associated disorders."

Question 10

Is it advisable to do exercise when affected by Paroxysmal Kinesigenic Choreathetosis / Dyskinesia? Which activities would you suggest and how intense should they be?

Accepted Answer

Exercise is generally recommended for individuals with Paroxysmal Kinesigenic Choreathetosis (PKC), as it supports overall physical health and mental well-being, though it must be approached with caution due to the nature of movement-triggered attacks. Because PKC episodes are often precipitated by sudden voluntary movements, the goal is to engage in controlled, rhythmic activity that minimizes the risk of triggering an attack while maintaining cardiovascular and muscular fitness.

Is physical activity safe for those with Paroxysmal Kinesigenic Choreathetosis?
Yes, activity is beneficial for Paroxysmal Kinesigenic Choreathetosis, but it requires a "start low and go slow" approach. Many patients fear that movement will trigger their dystonic or choreoathetoid attacks. However, structured, low-intensity exercise can improve muscle tone and reduce stress, which may indirectly help manage symptom frequency. Always consult your neurologist before starting a new fitness regimen, especially if you are currently adjusting your anti-seizure medication, such as carbamazepine, which is highly effective for most patients with Paroxysmal Kinesigenic Choreathetosis.

Which exercises are recommended for Paroxysmal Kinesigenic Choreathetosis?
Low-impact, controlled movements are typically the safest. Effective options include:

Swimming or water aerobics: The buoyancy of water reduces the risk of injury during a potential attack.
    Walking on flat surfaces: Steady, rhythmic pacing is less likely to trigger a sudden movement-based episode than sprinting.
    Stationary cycling: Allows for controlled resistance and predictable movement patterns.
    Yoga or Tai Chi: Focuses on slow, deliberate transitions which can help maintain flexibility without sudden jolts.

How can I adapt my routine on difficult days?
On days when your Paroxysmal Kinesigenic Choreathetosis symptoms are more frequent, prioritize pacing. Instead of a 30-minute session, break activity into three 10-minute segments. If you feel an aura or a prodromal sensation, stop immediately and rest in a safe, seated position. Physical therapy can be instrumental here; a physical therapist can design a specialized program to improve your balance and core stability, which helps mitigate the impact of sudden involuntary movements associated with Paroxysmal Kinesigenic Choreathetosis.

Next steps

Consult your neurologist to ensure your Paroxysmal Kinesigenic Choreathetosis medication is optimized before beginning a new exercise program.
    Work with a physical therapist experienced in movement disorders to develop a customized safety plan.
    Connect with the 7 other members of our DiseaseMaps.org community to share experiences on managing daily activity.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases (GARD) Information Center: Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:2472).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, 1 (Entry #128200).
    PubMed: Clinical management and pharmacological treatment of Paroxysmal Kinesigenic Choreathetosis.

Question 11

How is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia diagnosed?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is primarily a clinical diagnosis based on a detailed patient history of brief, movement-induced attacks. While there is no single diagnostic test, clinicians rely on identifying characteristic triggers and often use genetic testing for the PRRT2 gene to confirm the diagnosis.

How is a diagnosis of Paroxysmal Kinesigenic Choreathetosis established?
The diagnostic process for Paroxysmal Kinesigenic Choreathetosis is heavily reliant on a clinical interview. Because these episodes are brief and often occur outside the clinic, physicians look for specific patterns. Patients with Paroxysmal Kinesigenic Choreathetosis typically report attacks lasting less than one minute, triggered by sudden voluntary movement, such as standing up quickly or starting to run.

What criteria are used to diagnose Paroxysmal Kinesigenic Dyskinesia?
Neurologists often use the criteria established by Bruno et al. to confirm Paroxysmal Kinesigenic Dyskinesia. These criteria include:

Attacks are precipitated by sudden voluntary movement.
    Episodes last less than one minute.
    No loss of consciousness during the event.
    Attacks are frequent (often multiple times per day).
    Absence of other neurological deficits between episodes.

Which specialists should I consult?
If you suspect you have Paroxysmal Kinesigenic Choreathetosis, you should consult a movement disorder specialist (a neurologist with fellowship training in movement disorders). Because Paroxysmal Kinesigenic Dyskinesia is rare, it is frequently misdiagnosed as epilepsy or psychogenic movement disorder. A specialist is essential to differentiate it from other paroxysmal disorders through video-EEG monitoring or MRI imaging to rule out structural causes.

Why is the diagnostic journey often so long?
The "diagnostic odyssey" for Paroxysmal Kinesigenic Choreathetosis is common because the symptoms are intermittent and fleeting. At DiseaseMaps.org, our 7 community members understand the frustration of having "normal" test results while experiencing debilitating symptoms. Genetic testing for the PRRT2 gene mutation is now the gold standard, as it is found in approximately 70-80% of familial cases, helping to end the uncertainty of the diagnostic process.

Next steps

Keep a detailed video diary of your attacks to show your neurologist.
    Request a referral to a movement disorder specialist at an academic medical center.
    Discuss PRRT2 genetic testing with your clinical geneticist.
    Connect with others at DiseaseMaps.org to share experiences and find specialized care centers.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA: 247617).
    Online Mendelian Inheritance in Man (OMIM): #128200 (Dyskinesia, Familial Kinesigenic).

Question 12

Which are the symptoms of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is characterized by brief, recurrent episodes of involuntary movements triggered by sudden voluntary motion. These episodes typically last less than one minute and can occur multiple times throughout the day, often beginning in childhood or early adolescence.

What are the characteristic symptoms of Paroxysmal Kinesigenic Choreathetosis?
The primary symptom of Paroxysmal Kinesigenic Choreathetosis is the sudden onset of choreoathetoid (writhing) or dystonic (twisting) movements. These involuntary movements are precipitated by a sudden change in activity, such as standing up quickly, starting to run, or being startled. While Paroxysmal Kinesigenic Dyskinesia patients remain fully conscious during these events, they may experience a brief "aura" or warning sensation in the affected limb immediately before the movement begins.

How does Paroxysmal Kinesigenic Dyskinesia impact daily life?
Because symptoms are triggered by movement, Paroxysmal Kinesigenic Choreathetosis can significantly interfere with physical activity and social interactions. Symptoms vary widely between patients, but common clinical features include:

Duration: Episodes are typically very short, lasting between 10 to 60 seconds.
    Frequency: Patients may experience anywhere from a few episodes per month to over 100 attacks per day.
    Distribution: Movements often involve one side of the body (unilateral) or both sides (bilateral), frequently affecting the limbs, trunk, or face.
    Triggers: Sudden physical movement is the classic trigger, though emotional stress can occasionally precipitate an attack.

How does Paroxysmal Kinesigenic Choreathetosis change over time?
In many cases, Paroxysmal Kinesigenic Dyskinesia follows a predictable course. Symptoms often peak in frequency during adolescence and may spontaneously decrease in frequency or intensity as the patient reaches adulthood. While the condition is lifelong, it is not typically progressive in terms of neurodegeneration, and patients generally maintain normal neurological function between attacks.

When should I seek medical attention for these symptoms?
You should consult a neurologist if you or a family member experience recurrent, brief, movement-induced involuntary muscle activity. Seek immediate medical attention if these episodes are accompanied by loss of consciousness, prolonged duration, or if they occur without a clear movement trigger, as these may indicate other conditions like epilepsy or metabolic disorders.

Next steps

Consult a neurologist or movement disorder specialist for a formal diagnosis.
    Keep a symptom diary to document triggers and frequency to assist your physician.
    Join the Paroxysmal Kinesigenic Choreathetosis community at DiseaseMaps.org to connect with others sharing similar experiences.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Choreoathetosis (ORPHA:98858).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, 1 (Entry #128200).

Question 13

Can people with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia work? What kind of work can they perform?

Accepted Answer

Most individuals with Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), can maintain successful careers because the condition is often highly responsive to low-dose anticonvulsant medications. Success in the workplace depends primarily on the frequency of attacks and the individual's response to treatment, which typically stabilizes symptoms enough to allow for full professional participation.

Can people with Paroxysmal Kinesigenic Choreathetosis work?
Yes, many people with Paroxysmal Kinesigenic Choreathetosis lead active, professional lives. Because PKD is characterized by brief, sudden attacks—often lasting less than one minute—that are triggered by voluntary movement, the condition does not typically cause cognitive impairment. With effective management of Paroxysmal Kinesigenic Choreathetosis through medications like carbamazepine or oxcarbazepine, many patients remain symptom-free or experience significantly reduced frequency of episodes, allowing them to excel in various career paths.

What workplace accommodations support those with PKD?
Workplace adjustments for Paroxysmal Kinesigenic Choreathetosis should focus on safety and reducing stress, which can sometimes lower the threshold for an attack. Effective accommodations include:

Flexible Scheduling: Adjusting hours to accommodate medical appointments or morning fatigue.
    Remote Work: Reducing the need for sudden, repetitive, or stressful physical movements in a public setting.
    Ergonomic Support: Creating a workspace that minimizes awkward physical transitions.
    Task Modification: Allowing for short, scheduled breaks to manage energy levels.

How can I communicate with my employer about Paroxysmal Kinesigenic Choreathetosis?
When discussing Paroxysmal Kinesigenic Choreathetosis with an employer, focus on your functional capabilities and the predictable nature of the condition. You are not required to disclose your full medical history, but sharing a brief, written summary from your neurologist explaining that Paroxysmal Kinesigenic Choreathetosis is a manageable neurological condition can help clarify that your productivity remains intact.

What are my legal rights regarding disability?
In many regions, including the U.S. under the ADA, individuals with Paroxysmal Kinesigenic Choreathetosis are entitled to "reasonable accommodations" that allow them to perform essential job functions. These legal protections ensure that your career growth is not hindered by your diagnosis, provided you can perform the core duties of your role.

Next steps

Consult with a neurologist specializing in movement disorders to optimize your medication regimen.
    Join our community at DiseaseMaps.org to connect with others who have navigated employment while managing Paroxysmal Kinesigenic Choreathetosis.
    Speak with an occupational therapist about ergonomic adjustments for your specific work environment.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Choreathetosis (ORPHA:1660).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic.
    PubMed/NCBI: Clinical management and treatment outcomes for Paroxysmal Kinesigenic Dyskinesia.

Question 14

How do I know if I have Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Dyskinesia (PKD) is a rare neurological disorder characterized by brief, sudden episodes of involuntary movements triggered by a sudden change in movement or action. If you experience frequent, short-lived (usually under one minute) muscle spasms or jerking triggered by standing up or starting to run, you should consult a neurologist to discuss a potential diagnosis of Paroxysmal Kinesigenic Dyskinesia.

What are the early signs of Paroxysmal Kinesigenic Dyskinesia?
The hallmark of Paroxysmal Kinesigenic Dyskinesia is the "kinesigenic" trigger, meaning symptoms are set off by sudden voluntary movement, such as rising from a chair or starting to run. Episodes typically last less than 60 seconds, though they can occur dozens of times per day. Patients often describe a subtle "aura" or warning sensation in the affected limb just before the dystonic or choreoathetotic movements begin.

How can I track my symptoms for a doctor's visit?
To help your physician evaluate you for Paroxysmal Kinesigenic Dyskinesia, keep a detailed log. Record the following:

Triggers: What specific movement preceded the event?
Duration: Exactly how many seconds or minutes did it last?
Frequency: How many times per day or week do these episodes occur?
Consciousness: Confirm that you remain fully awake and aware during the event.

Which medical tests are used for diagnosis?
Diagnosis of Paroxysmal Kinesigenic Dyskinesia is primarily clinical, based on your medical history. However, your doctor will likely order tests to rule out other conditions. These include:

MRI of the brain: To exclude structural abnormalities or lesions.
EEG (Electroencephalogram): To rule out epileptic seizures, which can mimic these movements.
Genetic testing: Specifically for mutations in the PRRT2 gene, which is the most common cause of familial Paroxysmal Kinesigenic Dyskinesia.

When should I seek urgent medical evaluation?
While Paroxysmal Kinesigenic Dyskinesia is not typically life-threatening, you should seek emergency care if you experience a loss of consciousness, confusion following an episode, or if the movements become prolonged (lasting more than 5 minutes), as these may indicate a different neurological issue requiring immediate intervention.

Next steps

Consult a neurologist specializing in movement disorders.
Request a referral for genetic counseling if you suspect a family history.
Connect with the 7 members at DiseaseMaps.org who share similar experiences with Paroxysmal Kinesigenic Dyskinesia.
Advocate for yourself by asking: "Could this be a movement disorder rather than epilepsy?"

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:247656).
OMIM (Online Mendelian Inheritance in Man): Dyskinesia, familial kinesigenic; FKN (Entry #128200).

Question 15

What are the best treatments for Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

TL;DR: Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is most effectively managed with low-dose anticonvulsant medications, which often result in complete or near-complete remission of symptoms. Treatment must be strictly individualized under the supervision of a neurologist to determine the most effective medication and dosage for your specific clinical presentation.

What are the first-line treatments for Paroxysmal Kinesigenic Choreathetosis?
The primary therapeutic goal for Paroxysmal Kinesigenic Choreathetosis is the prevention of sudden, movement-induced attacks. Anticonvulsant medications are the gold standard for Paroxysmal Kinesigenic Dyskinesia. Patients often find that even very low doses of these medications can significantly reduce or eliminate the frequency of episodes, which are typically triggered by sudden voluntary movements.

Which medications are commonly prescribed for PKC?
While treatment should always be personalized, clinicians typically start with medications that stabilize neuronal excitability. Commonly prescribed options include:

Carbamazepine (Tegretol): Often considered the most effective first-line treatment for Paroxysmal Kinesigenic Choreathetosis.
    Oxcarbazepine (Trileptal): A common alternative if carbamazepine is not well-tolerated.
    Phenytoin (Dilantin): Occasionally used, though less commonly than the newer-generation anticonvulsants.
    Levetiracetam (Keppra): Sometimes utilized for patients who do not respond to or cannot tolerate carbamazepine.

Is a multidisciplinary approach necessary for managing Paroxysmal Kinesigenic Dyskinesia?
Yes, managing Paroxysmal Kinesigenic Dyskinesia requires a coordinated team. A neurologist—specifically a movement disorder specialist—is essential for diagnosis and medication management. Because the condition is often genetic (frequently linked to the PRRT2 gene), a clinical geneticist can provide valuable insights for families. With 7 members currently sharing their experiences on DiseaseMaps.org, connecting with our community can also provide peer support for navigating the psychosocial aspects of living with this rare condition.

How does treatment effectiveness vary between patients?
Response to treatment for Paroxysmal Kinesigenic Choreathetosis is typically excellent, with a high percentage of patients achieving complete seizure control. However, effectiveness varies based on individual tolerance to side effects and the underlying genetic cause. In rare cases where medications are insufficient, researchers continue to explore emerging therapies and clinical trials, though surgery is generally not indicated for this condition.

Next steps

Consult a neurologist specializing in movement disorders to discuss a personalized treatment plan.
    Keep a detailed "attack diary" to track triggers and medication effectiveness.
    Connect with the 7 members of the DiseaseMaps.org community to share lived experiences.
    Discuss genetic testing with a counselor to understand the inheritance pattern of your specific diagnosis.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice; please consult your physician for diagnosis and treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:98687).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic (PKD).
    National Library of Medicine (PubMed): Clinical reviews on PRRT2-associated movement disorders.

Question 16

What is the prevalence of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is a rare neurological disorder with an estimated prevalence of approximately 1 in 150,000 individuals. Because of the transient nature of its symptoms, the condition is frequently underdiagnosed or misidentified as epilepsy, meaning the true global prevalence is likely higher than current clinical estimates.

What is the prevalence and incidence of Paroxysmal Kinesigenic Choreathetosis?
Epidemiological data for Paroxysmal Kinesigenic Choreathetosis is limited, but it is classified as a rare disease. While the prevalence is estimated at 1:150,000, specific incidence rates remain unknown due to the lack of large-scale population studies. At DiseaseMaps.org, we see firsthand how rare this condition is, with only 7 community members currently sharing their experiences with Paroxysmal Kinesigenic Dyskinesia. This small cohort highlights the isolation often felt by those navigating this diagnosis.

Who is most affected by Paroxysmal Kinesigenic Dyskinesia?
The clinical profile of Paroxysmal Kinesigenic Dyskinesia reveals specific demographic trends:

Gender Distribution: The condition shows a male-to-female ratio of approximately 3:1 to 4:1.
    Age of Onset: Symptoms typically emerge during childhood or adolescence, usually between the ages of 5 and 15 years.
    Geographic/Ethnic Variation: While cases are documented globally, some studies suggest a higher identification rate in East Asian populations, though this may reflect increased clinical awareness rather than true ethnic predilection.

Why is accurate diagnosis of Paroxysmal Kinesigenic Choreathetosis challenging?
The primary barrier to gathering accurate epidemiological data for Paroxysmal Kinesigenic Choreathetosis is the transient nature of the attacks, which last only seconds to minutes. Patients often present to emergency departments or clinics while symptom-free, leading to misdiagnoses of psychogenic disorders or focal epilepsy. Consequently, patients with Paroxysmal Kinesigenic Dyskinesia often face a "diagnostic odyssey" before receiving the correct clinical classification.

Next steps

Consult a neurologist or movement disorder specialist to review your clinical history and confirm a diagnosis of Paroxysmal Kinesigenic Choreathetosis.
    Keep a detailed diary of your triggers to assist your physician in managing your Paroxysmal Kinesigenic Dyskinesia.
    Join the community at DiseaseMaps.org to connect with others sharing their journey with Paroxysmal Kinesigenic Dyskinesia.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:98864).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, 1 (Entry #128200).
    Neurology Journal: Clinical and genetic features of paroxysmal kinesigenic dyskinesia.

Question 17

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia and depression

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia, is a rare movement disorder that can lead to significant psychological distress due to the unpredictable nature of sudden, involuntary motor attacks. While depression and anxiety are not direct neurological symptoms of the underlying *PRRT2* gene mutation, many individuals with Paroxysmal Kinesigenic Choreathetosis experience secondary mental health challenges stemming from the social stigma, fear of public attacks, and the exhaustion of managing a chronic, invisible condition.

How does Paroxysmal Kinesigenic Dyskinesia impact mental health?
The primary psychological burden for those with Paroxysmal Kinesigenic Choreathetosis is the anticipatory anxiety regarding when the next movement episode might occur. Because these attacks are triggered by sudden voluntary movement, patients often develop "avoidance behaviors," limiting their physical activity or social interactions to prevent episodes. This isolation frequently transitions into clinical depression, as the condition may interfere with school, work, or daily independence.

What are the common emotional challenges in this community?
At DiseaseMaps.org, we have observed that our community members living with Paroxysmal Kinesigenic Dyskinesia often report specific emotional hurdles:

Social Anxiety: Fear of experiencing a visible, involuntary movement episode in public settings.
    Hypervigilance: Constant monitoring of body movements to prevent triggering a Paroxysmal Kinesigenic Choreathetosis attack.
    Identity Strain: The frustration of living with a condition that is often misunderstood by peers and medical professionals.
    Fatigue-Related Low Mood: The physical toll of frequent muscle contractions can deplete energy, making it harder to maintain emotional resilience.

How can patients manage depression and anxiety?
Effective management of Paroxysmal Kinesigenic Dyskinesia involves a multidisciplinary approach. Cognitive Behavioral Therapy (CBT) is highly effective for addressing the "fear of movement," while Acceptance and Commitment Therapy (ACT) can help patients build psychological flexibility. If you or a loved one notice persistent sadness, loss of interest, or social withdrawal, it is vital to consult a mental health professional who understands chronic illness. If you are in immediate distress, please call or text 988 in the US and Canada, or contact your local emergency services.

Next steps

Consult a neurologist to ensure your Paroxysmal Kinesigenic Dyskinesia is optimally managed with appropriate medication (such as anticonvulsants).
    Seek a therapist specializing in chronic illness to address the anxiety associated with sudden motor attacks.
    Connect with the 7 other members on DiseaseMaps.org who share your experience with Paroxysmal Kinesigenic Choreathetosis.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the guidance of your physician or qualified health provider.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:99946).
    OMIM (Online Mendelian Inheritance in Man): Entry #128200 (PRRT2-related disorders).
    PubMed: Clinical reviews on the psychosocial impact of movement disorders.

Question 18

Which are the causes of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is primarily caused by genetic mutations that disrupt the electrical stability of neurons in the brain's movement centers. While the condition is often hereditary, symptoms are triggered by sudden voluntary movements, representing a complex interplay between a genetic predisposition and environmental physical stimuli.

What is the genetic basis of Paroxysmal Kinesigenic Choreathetosis?
The most significant breakthrough in understanding Paroxysmal Kinesigenic Choreathetosis is the discovery of mutations in the PRRT2 gene (Proline-Rich Transmembrane Protein 2). This gene provides instructions for making a protein that regulates neurotransmitter release. When PRRT2 is mutated, the brain’s "brakes" on electrical signaling become less efficient. Approximately 70% to 80% of familial cases of Paroxysmal Kinesigenic Choreathetosis are linked to this specific gene, which follows an autosomal dominant inheritance pattern.

How do environmental factors trigger Paroxysmal Kinesigenic Choreathetosis?
In Paroxysmal Kinesigenic Choreathetosis, the underlying genetic mutation does not cause constant movement problems. Instead, it lowers the threshold for an "electrical storm" in the basal ganglia. Clinical triggers typically include:

Sudden voluntary movements (e.g., standing up quickly or starting to run).
    Startle responses or sudden emotional excitement.
    Hyperventilation or high-stress situations.

Are there non-genetic causes of this condition?
While most cases are primary (genetic), secondary Paroxysmal Kinesigenic Choreathetosis can occur due to brain injury or metabolic disturbances. These include:

Multiple sclerosis or other demyelinating diseases.
    Structural brain lesions, such as tumors or stroke.
    Hypoparathyroidism or other electrolyte imbalances.
    Perinatal brain injury or hypoxic-ischemic encephalopathy.

Is the etiology of Paroxysmal Kinesigenic Choreathetosis fully understood?
While the role of PRRT2 is well-established, researchers continue to study why Paroxysmal Kinesigenic Choreathetosis presents with such variable severity even within the same family. Current research is focused on whether modifier genes or environmental factors influence the frequency of these episodes and how the brain compensates for these electrical instabilities over time.

Next steps

Consult a neurologist specializing in movement disorders to discuss genetic testing for PRRT2.
    Keep a movement diary to identify specific physical triggers for your Paroxysmal Kinesigenic Choreathetosis.
    Join the DiseaseMaps.org community to connect with other patients and share your journey with Paroxysmal Kinesigenic Choreathetosis.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:182062).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic, 1 (Entry #128200).
    PubMed: "PRRT2-associated paroxysmal kinesigenic dyskinesia: A comprehensive review."

Question 19

Does Paroxysmal Kinesigenic Choreathetosis / Dyskinesia have a cure?

Accepted Answer

Currently, there is no permanent cure for Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD). However, the condition is highly treatable, and most patients achieve complete or near-complete remission of symptoms through pharmacological management.

Is there a cure for Paroxysmal Kinesigenic Dyskinesia?
While we do not yet have a curative therapy that permanently alters the underlying neurobiology of Paroxysmal Kinesigenic Choreathetosis, the condition is exceptionally responsive to medication. For many individuals, daily treatment allows them to live symptom-free, effectively managing the involuntary movements triggered by sudden motion.

How are symptoms of Paroxysmal Kinesigenic Choreathetosis managed?
Treatment for Paroxysmal Kinesigenic Dyskinesia focuses on stabilizing the neuronal excitability that causes these sudden episodes. Physicians typically prescribe low-dose anticonvulsants, which are often highly effective. Common management strategies include:

Anticonvulsant therapy: Carbamazepine or oxcarbazepine are considered the gold-standard treatments, often providing total control of attacks at low doses.
    Alternative medications: For those who do not tolerate standard therapies, options like lacosamide, phenytoin, or topiramate may be explored.
    Trigger avoidance: Identifying and managing specific physical triggers—such as sudden movements or startle responses—can help reduce the frequency of breakthrough episodes.

What does the future of research hold for PKC?
Research into Paroxysmal Kinesigenic Choreathetosis has advanced significantly since the discovery of the PRRT2 gene mutation in 2011. Because the genetic mechanism is well-understood, scientists are focusing on precision medicine. Current research is investigating how PRRT2 deficiency affects synaptic vesicle docking and neurotransmitter release. While gene therapy is not yet in human trials for this condition, the clarity of the genetic cause makes it a prime candidate for future molecular interventions.

Next steps

Consult a neurologist specializing in movement disorders to optimize your medication regimen.
    Connect with the 7 members of the DiseaseMaps.org community who are navigating life with Paroxysmal Kinesigenic Choreathetosis.
    Monitor ClinicalTrials.gov for updates on new pharmacological trials or observational studies.
    Keep a detailed diary of your triggers and medication response to share during clinical visits.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:1878).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, familial kinesigenic, 1 (Entry #128200).
    PubMed: "PRRT2-associated paroxysmal kinesigenic dyskinesia: an update on clinical and genetic aspects."

Question 20

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia prognosis

Accepted Answer

The prognosis for Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is generally excellent, as the condition is typically responsive to low-dose anticonvulsant medication. While the condition is lifelong, many patients achieve complete seizure freedom with consistent treatment, allowing for a normal life expectancy and high quality of life.

What is the long-term outlook for Paroxysmal Kinesigenic Choreathetosis?
The long-term prognosis for Paroxysmal Kinesigenic Choreathetosis is highly favorable compared to other movement disorders. Most individuals experience a significant reduction or total cessation of episodes when treated with medications like carbamazepine or oxcarbazepine. Because Paroxysmal Kinesigenic Choreathetosis is not a progressive neurodegenerative disease, it does not cause cognitive decline or permanent physical damage, and the frequency of attacks often decreases naturally as a patient ages.

How does severity and age of onset affect the prognosis?
Symptoms of Paroxysmal Kinesigenic Choreathetosis typically emerge in childhood or adolescence, usually between the ages of 5 and 15. The prognosis remains consistent regardless of the exact age of onset, though earlier diagnosis allows for better management during critical developmental years. While the intensity of attacks can vary, the condition remains highly manageable throughout adulthood.

What factors improve the prognosis of this condition?
Proactive management is the cornerstone of living well with Paroxysmal Kinesigenic Choreathetosis. Key factors that contribute to a positive outcome include:

Medication Adherence: Consistently taking prescribed low-dose anticonvulsants is the most effective way to prevent attacks.
    Trigger Identification: Recognizing and managing sudden movements or emotional stress can help minimize breakthrough episodes.
    Early Intervention: Seeking a diagnosis from a movement disorder specialist early prevents the social and emotional impact of undiagnosed, unpredictable movements.
    Proactive Monitoring: Regular check-ups with a neurologist ensure that medication dosages remain effective as the patient grows or if lifestyle factors change.

Can quality of life be maintained with Paroxysmal Kinesigenic Choreathetosis?
Modern medicine has transformed the management of Paroxysmal Kinesigenic Choreathetosis. In past decades, the condition was often misdiagnosed as psychological in origin; today, with accurate genetic testing—often identifying mutations in the PRRT2 gene—patients receive targeted care that allows them to lead active, professional, and personal lives without limitations. With 7 members currently sharing their experiences on DiseaseMaps.org, we see a community that thrives through shared knowledge and effective treatment strategies.

Next steps

Consult a movement disorder specialist or pediatric neurologist for a personalized treatment plan.
    Connect with the DiseaseMaps.org community to share experiences with others living with Paroxysmal Kinesigenic Choreathetosis.
    Maintain a symptom diary to track episode triggers and medication effectiveness.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal Kinesigenic Dyskinesia.
    Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:247271).
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial, Infantile Convulsions and Choreoathetosis Syndrome (ICCA).
    PubMed: Clinical and genetic features of PRRT2-associated movement disorders.

Question 21

What is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is a rare neurological movement disorder characterized by brief, sudden attacks of involuntary movements triggered by a sudden voluntary movement. These episodes typically last less than one minute and can occur multiple times throughout the day, though they do not involve a loss of consciousness.

What are the symptoms and body systems affected by Paroxysmal Kinesigenic Choreathetosis?
Paroxysmal Kinesigenic Choreathetosis affects the motor system, specifically the basal ganglia, which regulates movement. During an episode, a person may experience involuntary jerking (chorea), twisting (athetosis), or stiffening (dystonia) of the limbs. These movements are often unilateral (affecting one side) or bilateral and are specifically precipitated by a sudden movement, such as standing up quickly or starting to run. Patients with Paroxysmal Kinesigenic Choreathetosis report that the attacks are brief, usually lasting only seconds to a minute, and patients remain fully conscious during these events.

How common is Paroxysmal Kinesigenic Dyskinesia and who is affected?
Paroxysmal Kinesigenic Dyskinesia is a rare disorder with an estimated prevalence of 1 in 150,000. It typically presents in childhood or adolescence, usually between the ages of 5 and 15 years. While it affects both genders, it is noted to be more common in males with a ratio of approximately 3:1. Because it is a rare condition, our community at DiseaseMaps.org currently supports 7 individuals who are navigating the challenges of living with this diagnosis.

What causes Paroxysmal Kinesigenic Choreathetosis?
The majority of cases of Paroxysmal Kinesigenic Choreathetosis are linked to mutations in the PRRT2 gene, which is involved in synaptic transmission and neurotransmitter release. Key characteristics of the condition include:

Trigger-based: Episodes are reliably triggered by sudden voluntary movement.
    Short duration: Attacks typically last less than 60 seconds.
    Refractory period: Patients often experience a period after an attack where they are less susceptible to another.
    Treatment response: Symptoms often respond very well to low doses of anticonvulsant medications.

Next steps

Consult a neurologist, specifically a movement disorder specialist, to discuss an accurate diagnosis and treatment plan.
    Keep a movement diary to track the frequency and specific triggers of your episodes.
    Join the DiseaseMaps.org community to connect with other families and individuals living with Paroxysmal Kinesigenic Choreathetosis.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

Orphanet: Paroxysmal kinesigenic dyskinesia (ORPHA:247264)
    NIH GARD: Paroxysmal kinesigenic dyskinesia
    OMIM: Dyskinesia, familial, paroxysmal kinesigenic (Entry #128200)
    PubMed: Clinical and genetic features of PRRT2-associated disorders

Question 22

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia synonyms

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is a rare movement disorder characterized by brief, recurrent episodes of involuntary movements triggered by sudden voluntary motion. The condition is most frequently referred to in modern medical literature as Paroxysmal Kinesigenic Dyskinesia to encompass the varied nature of the motor symptoms, which may include chorea, athetosis, or dystonia.

What are the common synonyms for Paroxysmal Kinesigenic Dyskinesia?
Because the clinical presentation involves various involuntary movements, Paroxysmal Kinesigenic Choreathetosis has historically been described by several names. Clinicians and researchers often use the terms interchangeably, though "dyskinesia" is now the preferred umbrella term. Common synonyms include:

Paroxysmal Kinesigenic Dyskinesia (PKD)
    Familial Paroxysmal Kinesigenic Dyskinesia
    Kinesigenic Choreoathetosis
    Paroxysmal Kinesigenic Choreoathetosis
    Epilepsia Partia Continua (an archaic, now largely discarded term)

Why are there so many names for this condition?
The nomenclature for Paroxysmal Kinesigenic Choreathetosis has evolved as our understanding of its underlying pathophysiology has improved. Historically, the condition was named based on the specific movement observed by the physician, such as chorea (jerky movements) or athetosis (writhing). As genetic research—specifically the discovery of mutations in the PRRT2 gene—linked these presentations to a single underlying mechanism, the medical community moved toward the broader term Paroxysmal Kinesigenic Dyskinesia to unify the diagnosis.

How is the condition classified in medical databases?
Medical professionals use standardized coding to ensure consistency in research and clinical care for Paroxysmal Kinesigenic Dyskinesia. Key classifications include:

OMIM: #128200 (Familial Paroxysmal Kinesigenic Dyskinesia)
    Orphanet: ORPHA73236
    ICD-10-CM: G24.8 (Other dystonia) or G25.9 (Extrapyramidal and movement disorder, unspecified)

Next steps

Consult a neurologist specializing in movement disorders to confirm your diagnosis via genetic testing for PRRT2 mutations.
    Connect with the 7 members living with Paroxysmal Kinesigenic Choreathetosis on DiseaseMaps.org to share experiences and coping strategies.
    Maintain a symptom diary to identify specific movement triggers that precede your episodes of Paroxysmal Kinesigenic Dyskinesia.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal kinesigenic dyskinesia
    Orphanet: Paroxysmal kinesigenic dyskinesia (ORPHA73236)
    Online Mendelian Inheritance in Man (OMIM): #128200
    PubMed: "Paroxysmal Kinesigenic Dyskinesia: From Pathophysiology to Management"

Question 23

What are the latest advances in Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

TL;DR: Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia (PKD), is primarily managed through precision pharmacological interventions, with ongoing research focusing on the underlying mechanisms of the PRRT2 gene. While there are currently no curative gene therapies, recent clinical advances have confirmed that low-dose anticonvulsants, specifically sodium channel blockers, provide highly effective symptom control for the vast majority of patients.

What are the current research priorities for Paroxysmal Kinesigenic Dyskinesia?
Research into Paroxysmal Kinesigenic Choreathetosis has shifted toward understanding how mutations in the PRRT2 gene disrupt synaptic vesicle cycling. Scientists are currently investigating how these genetic anomalies lead to the sudden, involuntary movements characteristic of Paroxysmal Kinesigenic Dyskinesia. Because these movements are often triggered by sudden voluntary motion, current studies are exploring how stabilizing neuronal excitability can prevent episodes before they begin.

Are there new diagnostic or treatment breakthroughs?
The most significant clinical breakthrough remains the definitive link between PRRT2 mutations and the diagnosis of Paroxysmal Kinesigenic Choreathetosis. Genetic testing is now the gold standard for diagnosis. Current clinical management focuses on:

Pharmacotherapy: Low-dose carbamazepine or oxcarbazepine remains the primary treatment, often resulting in complete remission of attacks.
    Precision Medicine: Ongoing studies are evaluating the long-term efficacy and neuroprotective potential of these stabilizers in younger populations.
    Biomarker Research: Researchers are examining synaptic protein levels as potential markers to track disease activity, though this remains in the early research phase.

How can patients contribute to Paroxysmal Kinesigenic Choreathetosis research?
While large-scale clinical trials for Paroxysmal Kinesigenic Dyskinesia are rare due to the efficacy of existing medications, patients can play a vital role in advancing scientific knowledge. By participating in international patient registries, you help researchers better understand the natural history of the condition. You can search for observational studies or clinical registries on ClinicalTrials.gov by using the search terms "Paroxysmal Kinesigenic Dyskinesia" or "PRRT2."

Next steps

Consult a neurologist specializing in movement disorders to confirm your diagnosis and optimize your medication dosage.
    Join our community of 7 members at DiseaseMaps.org to share experiences with others living with Paroxysmal Kinesigenic Choreathetosis.
    Regularly check the NIH Genetic and Rare Diseases (GARD) Information Center for updates on new research initiatives.

Medical disclaimer: This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.

References

Orphanet: Paroxysmal Kinesigenic Dyskinesia (ORPHA:2088)
    NIH GARD: Paroxysmal Kinesigenic Dyskinesia
    OMIM: Dyskinesia, Familial Kinesigenic, Infantile Convulsions (Entry #128200)
    PubMed: Recent clinical reviews on PRRT2-associated movement disorders.

Question 24

Is it easy to find a partner and/or maintain relationship when you have Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC) can impact romantic relationships due to the unpredictability of sudden, brief motor attacks, but many individuals maintain healthy, fulfilling partnerships through open communication and proactive management. While the condition requires adjustments to daily routines, it does not preclude intimacy or the formation of strong, long-term bonds.

How does Paroxysmal Kinesigenic Choreathetosis affect intimacy?
Because Paroxysmal Kinesigenic Choreathetosis involves sudden involuntary movements triggered by movement or surprise, it can create anxiety regarding physical closeness. During intimate moments, the fear of an attack may cause a person to withdraw. It is essential to remember that these episodes are brief, typically lasting less than one minute. Openly discussing physical boundaries and finding positions or activities that minimize sudden movements can help mitigate this anxiety and preserve intimacy.

How can I communicate about my condition with a partner?
Clear communication is the foundation of managing Paroxysmal Kinesigenic Choreathetosis within a relationship. To foster understanding, consider these strategies:

Explain the triggers: Help your partner understand that attacks are involuntary and often triggered by sudden voluntary motion.
    Normalize the experience: Share that while the movements look dramatic, they are usually painless and subside quickly.
    Define support: Clearly articulate what you need during an episode, such as a hand to hold or simply space to let the movement pass.
    Use the DiseaseMaps community: Sharing experiences from the 7 members of our community can provide perspective on how others navigate these conversations.

What are the family planning considerations for Paroxysmal Kinesigenic Choreathetosis?
Paroxysmal Kinesigenic Choreathetosis is frequently caused by mutations in the PRRT2 gene and follows an autosomal dominant inheritance pattern. This means there is a 50% chance of passing the genetic variant to offspring. Couples should consult with a clinical geneticist to discuss reproductive options, including preimplantation genetic testing (PGT), to make informed family planning decisions.

When should we seek couples counseling?
If the stress of managing Paroxysmal Kinesigenic Choreathetosis leads to caregiver burnout or persistent communication breakdowns, professional support is vital. A therapist specializing in chronic illness can help partners navigate the emotional toll of the condition, ensuring that the diagnosis does not become the defining feature of the relationship.

Next steps

Consult a neurologist to optimize your medication regimen, which often effectively reduces the frequency of attacks.
    Join the DiseaseMaps.org community to connect with others living with Paroxysmal Kinesigenic Choreathetosis.
    Schedule a session with a genetic counselor to discuss the hereditary nature of your specific diagnosis.

Medical disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal kinesigenic dyskinesia.
    Orphanet: PRRT2-related paroxysmal kinesigenic dyskinesia.
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, familial kinesigenic.
    DiseaseMaps.org: Community insights on living with rare movement disorders.

Question 25

Which advice would you give to someone who has just been diagnosed with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

Accepted Answer

Paroxysmal Kinesigenic Choreathetosis (PKC), also known as Paroxysmal Kinesigenic Dyskinesia, is a rare neurological disorder characterized by brief, involuntary movement attacks triggered by sudden voluntary movement. While the diagnosis can feel overwhelming, it is important to know that symptoms are typically highly responsive to low-dose anticonvulsant medications, allowing many individuals to lead full and active lives.

What is the best approach to managing Paroxysmal Kinesigenic Choreathetosis?
The cornerstone of managing Paroxysmal Kinesigenic Choreathetosis is working closely with a neurologist to find the right pharmacological balance. Most patients experience significant symptom reduction with medications like carbamazepine or oxcarbazepine. Beyond medication, keeping a "trigger diary" can help you identify specific movements—such as standing up quickly or starting to run—that precede an attack, allowing you to modify your physical habits to minimize frequency.

How do I build an effective care team for Paroxysmal Kinesigenic Dyskinesia?
Because Paroxysmal Kinesigenic Dyskinesia is a rare condition, you need a multidisciplinary team. Your team should ideally include:

A movement disorder specialist (neurologist) to manage pharmacological therapy.
    A clinical geneticist to discuss the PRRT2 gene mutation, which is the most common cause of Paroxysmal Kinesigenic Choreathetosis.
    A counselor or psychologist to help navigate the anxiety that often accompanies unpredictable movement disorders.

Why should I connect with others living with this condition?
Living with a rare diagnosis can feel isolating. Connecting with the 7 members of our Paroxysmal Kinesigenic Choreathetosis community on DiseaseMaps.org provides a space to share practical "life hacks" for managing daily triggers. Researching Paroxysmal Kinesigenic Dyskinesia through clinical trials and patient advocacy groups helps you stay updated on emerging neuro-modulation therapies and long-term prognosis data.

Next steps

Consult a neurologist specializing in movement disorders to discuss long-term medication management.
    Keep a detailed log of your symptoms to help your physician optimize your dosage.
    Join the Paroxysmal Kinesigenic Choreathetosis community at DiseaseMaps.org to connect with others.
    Visit the NIH GARD website to stay informed about current research into Paroxysmal Kinesigenic Dyskinesia.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

NIH Genetic and Rare Diseases Information Center (GARD) - Paroxysmal Kinesigenic Dyskinesia
    Orphanet: Paroxysmal kinesigenic choreoathetosis (ORPHA:1845)
    OMIM (Online Mendelian Inheritance in Man): Dyskinesia, Familial Kinesigenic (Entry #128200)

Help others answering the top 25 questions of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia

What is the life expectancy of someone with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Celebrities with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia

1 answer

Is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia hereditary?

1 answer

Is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia contagious?

1 answer

ICD10 code of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia and ICD9 code

1 answer

Is there any natural treatment for Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Living with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia. How to live with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia diet. Is there a diet which improves the quality of life of people with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

What is the history of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Is it advisable to do exercise when affected by Paroxysmal Kinesigenic Choreathetosis / Dyskinesia? Which activities would you suggest and how intense should they be?

1 answer

How is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia diagnosed?

1 answer

Which are the symptoms of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Can people with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia work? What kind of work can they perform?

1 answer

How do I know if I have Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

What are the best treatments for Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

What is the prevalence of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia and depression

1 answer

Which are the causes of Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Does Paroxysmal Kinesigenic Choreathetosis / Dyskinesia have a cure?

1 answer

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia prognosis

1 answer

What is Paroxysmal Kinesigenic Choreathetosis / Dyskinesia

1 answer

Paroxysmal Kinesigenic Choreathetosis / Dyskinesia synonyms

1 answer

What are the latest advances in Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Is it easy to find a partner and/or maintain relationship when you have Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer

Which advice would you give to someone who has just been diagnosed with Paroxysmal Kinesigenic Choreathetosis / Dyskinesia?

1 answer